|Dr. David T. Hung M.D.||Founder, Pres, CEO & Director||1.16M||N/A||1958|
|Ms. Jennifer A. Fox||Chief Financial Officer||557.9k||N/A||1972|
|Dr. Gary Hattersley Ph.D.||Chief Scientific Officer||687.88k||N/A||1967|
|Ms. Stacy Markel||Sr. VP of HR||N/A||N/A||1965|
|Dr. Sergey Yurasov||Chief Medical Officer||N/A||N/A||1969|
|Dr. Lisa V. DeLuca B.S., M.S., Ph.D.||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. David C. Hanley Ph.D.||Chief Technical Operations Officer||N/A||N/A||1970|
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.